

1776 – 2026

United
States
of
America



UNITED STATES
PATENT AND
TRADEMARK OFFICE

Celebrating 250 years of life, liberty,
and the pursuit of innovation



The Director

*of the United States Patent and Trademark Office has received
an application for a patent for a new and useful invention. The title
and description of the invention are enclosed. The requirements
of law have been complied with, and it has been determined that
a patent on the invention shall be granted under the law.*

Therefore, this United States

Patent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

John A. S. Jones
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



US012584926B2

(12) **United States Patent**
Srinivasan et al.

(10) **Patent No.:** **US 12,584,926 B2**
(45) **Date of Patent:** **Mar. 24, 2026**

(54) **METHODS FOR IDENTIFYING
HAEMOGLOBIN S OR C IN A BIOLOGICAL
SAMPLE AND KITS THEREOF**

FOREIGN PATENT DOCUMENTS

EP 3076333 A1 10/2016
WO WO2019202410 A1 10/2019

(71) Applicant: **Indian Institute of Science**, Bangalore
(IN)

OTHER PUBLICATIONS

(72) Inventors: **Rajesh Srinivasan**, Bangalore (IN);
Eugene Christo V R, Bangalore (IN);
Prateek Katare, Bangalore (IN);
Aravind Venukumar, Bangalore (IN);
Sai Siva Gorthi, Bangalore (IN);
Nisanth KM Nambison, Bhopal (IN)

Akuwudike et al., Absorption Spectra of Normal Adult and Sick Cell Haemoglobins Treated With Hydrogen Peroxide at Two pH Values, *Adv. Biores.* vol. 1 [2] Dec. 2010, p. 55-60.

Almulla et al., Visible and near-infrared absorption properties of blood from sickle cell patients and normal Individuals, *Royal College of Surgeons in Ireland Student Medical Journal* 2011;4(1):82-83.

Bond et al., Towards a point-of-care strip test to diagnose sickle cell anemia, *PLoS One*. May 16, 2017;12(5): e0177732.

Hockham et al., The spatial epidemiology of sickle-cell anaemia in India, *Sci Rep* 8, 17685 (2018).

Masilamani et al., Spectral detection of sickle cell anemia and thalassemia, *Photodiagnosis Photodyn Ther.* Dec. 2013;10(4):429-33.

Masilamani et al., A Novel Technique of Spectral Discrimination of Variants of Sickle Cell Anemia, *Disease Markers*, vol. 2018, Article ID 5942368, 7 pages, 2018.

Patel et al., Oxygen Dissociation Assay (ODA): spectrophotometric based screening platform for hemoglobin-O₂ affinity modifiers, *BMG Labtech Resources Application notes* AN337, Rev. Jun. 2019.

Pietry et al., A Paper-Based Test for Screening Newborns for Sickle Cell Disease, *Sci Rep.* Apr. 3, 2017;7:45488.

Randolph et al., Novel Test Method (Sickle Confirm) to Differentiate Sickle Cell Anemia from Sickle Cell Trait for Potential Use in Developing Countries, *Clin Lab Sci.* Winter 2012;25(1):26-34.

Yang et al., A simple, rapid, low-cost diagnostic test for sickle cell disease, *Lab Chip.* Apr. 21, 2013;13(8):1464-7.

* cited by examiner

Primary Examiner — Maureen Wallenhorst

(74) *Attorney, Agent, or Firm* — Bret E. Field; Bozicevic, Field & Francis LLP

(57) **ABSTRACT**

The present disclosure provides in vitro methods for identifying the presence or absence of haemoglobin S (HbS) or haemoglobin C (HbC) in a blood sample, kits and devices thereof. The inventors have found that HbS shows a substantial decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The inventors expect HbC to show a similar decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The methods, kits and devices of the disclosure employ this decrease in absorption under deoxygenated conditions to identify the presence or absence of HbS or HbC in a blood sample. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of HbS or HbC in a blood sample in a point-of-care setting.

9 Claims, 3 Drawing Sheets

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1053 days.

(21) Appl. No.: **17/684,777**

(22) Filed: **Mar. 2, 2022**

(65) **Prior Publication Data**

US 2022/0283188 A1 Sep. 8, 2022

(30) **Foreign Application Priority Data**

Mar. 3, 2021 (IN) 202141009024

(51) **Int. Cl.**
G01N 33/72 (2006.01)
G01N 21/31 (2006.01)
G01N 33/49 (2006.01)

(52) **U.S. Cl.**
CPC **G01N 33/721** (2013.01); **G01N 21/31**
(2013.01); **G01N 33/49** (2013.01); **G01N**
2333/805 (2013.01); **G01N 2800/22** (2013.01)

(58) **Field of Classification Search**
CPC .. G01N 33/49; G01N 33/721; G01N 33/6893;
G01N 21/31; G01N 21/314; G01N
2333/805; G01N 2800/22
USPC 436/63, 66, 164; 422/82.05, 82.09
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,623,659 B2 1/2014 Randolph
9,995,757 B2 6/2018 Rice et al.
10,690,652 B2 6/2020 Znaty et al.
2005/0118654 A1 * 6/2005 Blomberg C07K 16/18
530/391.1
2015/0323521 A1 * 11/2015 Randolph G01N 33/721
435/29
2024/0241141 A1 * 7/2024 Gurkan G01N 21/31